Lung Cancer
IND168020; EIK1001-008: A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).
- Details
ClinicalTrials.gov ID:
NCT07365319
Diagnosis Type:
NA
USOR Number:
- Address
,
P: